免疫检查点抑制剂相关甲状腺功能减退症的最佳左甲状腺素给药策略:一项回顾性研究
该回顾性研究纳入109例免疫检查点抑制剂(ICI)相关甲状腺功能减退症患者,比较快速与常规滴定策略,发现快速滴定策略可显著提高游离甲状腺素和TSH正常化的累积发生率(HR分别为4.44和4.11),且安全性相当;短暂性甲状腺毒症后出现明显甲减者所需左甲状腺素剂量更高(平均差0.23 μg/kg/day)。
要点
- 短暂性甲状腺毒症后明显甲减者较孤立性明显甲减者需更高左甲状腺素剂量,平均差0.23 μg/kg/day(95% CI,0.08-0.38)。
- 快速滴定策略较常规策略显著提高游离甲状腺素和TSH正常化的累积发生率,HR分别为4.44(95% CI,2.24-8.82)和4.11(95% CI,2.18-7.73)。
- 快速滴定策略安全性相当,未显著增加不良反应。
核心结论
- 左甲状腺素需求量因ICI相关甲状腺功能减退症亚型而异,快速滴定策略较常规左甲状腺素替代治疗缩短达到甲状腺功能正常状态的时间,且未显著增加不良反应。
研究设计与样本
- 回顾性研究,纳入109例ICI相关甲状腺功能减退症患者,比较快速与常规滴定策略,主要结局为游离甲状腺素和TSH达到正常水平的时间。
主要发现
- 短暂性甲状腺毒症后明显甲减者较孤立性明显甲减者达到甲状腺功能正常状态所需左甲状腺素剂量更高,平均差0.23 μg/kg/day(95% CI,0.08-0.38)。
- 在ICI相关明显甲减且无心脏病、末次记录TSH低或正常后4周内TSH升高的患者中,快速滴定策略较常规策略显著提高游离甲状腺素正常化的累积发生率(HR 4.44;95% CI,2.24-8.82)。
- 快速滴定策略较常规策略显著提高TSH正常化的累积发生率(HR 4.11;95% CI,2.18-7.73)。
- 快速滴定策略与常规策略安全性相当。
关键数值与推荐
- 甲状腺功能正常状态预测左甲状腺素剂量(μg/kg/day)=(-0.016×体重)+(0.109×基线TSH水平)+2.661,适用于短暂性甲状腺毒症后明显甲减患者。
临床怎么用
- 对ICI相关明显甲减且无心脏病、末次记录TSH低或正常后4周内TSH升高的患者,可采用快速滴定策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune checkpoint inhibitor (ICI)-related hypothyroidism is mostly irreversible and prompt thyroid hormone replacement therapy is crucial, especially for patients undergoing neoadjuvant immunotherapy. OBJECTIVE: This study aimed to propose a novel titration strategy for ICI-related hypothyroidism, evaluate levothyroxine (LT4) dose differences between hypothyroidism patterns, and develop a predictive equation for the optimal LT4 dose. DESIGN: Retrospective study. SETTING: Tertiary academic hospital. PATIENTS: A total of 109 patients with ICI-related hypothyroidism. INTERVENTIONS: Rapid vs conventional titration strategy. MAIN OUTCOME MEASURES: The time to achieve normal free thyroxine and TSH levels. RESULTS: Patients with transient thyrotoxicosis followed by overt hypothyroidism required higher LT4 doses to achieve a euthyroid state compared to isolated overt hypothyroidism, with a mean difference of 0.23 μg/kg/day (95% CI, 0.08-0.38). In patients with ICI-related overt hypothyroidism and no cardiac disease, who had elevated TSH levels within 4 weeks of the last documented low or normal TSH, a rapid titration strategy was implemented. This strategy significantly improved the cumulative incidence of achieving normal free thyroxine and TSH levels compared to conventional titration strategy (hazard ratio, 4.44; 95% CI, 2.24-8.82; and hazard ratio, 4.11; 95% CI, 2.18-7.73, respectively), with a comparable safety profile. Predicted LT4 dose at euthyroid state (µg/kg/day) = (-0.016 × body weight) + (0.109 × baseline TSH level) + 2.661 for patients with thyrotoxicosis followed by overt hypothyroidism. CONCLUSION: LT4 requirements vary depending on the subtype of ICI-related hypothyroidism. The rapid titration strategy reduced the time to achieve a euthyroid state without a significant increase in adverse effects compared to conventional LT4 replacement therapy.
引用
- Gao Y, Du C, Xu Y, et al. Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study. J Clin Endocrinol Metab. 2025. PMID: 40317186. doi:10.1210/clinem/dgaf260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。